J Korean Med Sci.
2003 Apr;18(2):242-247. 10.3346/jkms.2003.18.2.242.
Autologous Stem Cell Transplantation for the Treatment of Neuroblastoma in Korea
- Affiliations
-
- 1Department Pediatrics, College of Medicine, Seoul National University Children's Hospital, 28 Yongon-dong, Chongno-gu, Seoul, Korea. hsahn@snu.ac.kr
- 2Department Pediatrics, Ewha Womans University College of Medicine, Seoul, Korea.
- 3Department Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
- 4Department Pediatrics, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 5Department Pediatrics, Chonnam National University Medical School, Gwangju, Korea.
- 6Department Pediatrics, Ajou University College of Medicine, Suwon, Korea.
- 7Department Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
- 8Department Pediatrics, University of Ulsan College of Medicine, Seoul, Korea.
- 9Department Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
- 10Department Pediatrics, Dong-A University College of Medicine, Busan, Korea.
- 11Department Pediatrics, Hanyang University College of Medicine, Seoul, Korea.
- 12Department Pediatrics, Hallym University College of Medicine, Seoul, Korea.
- 13Department Pediatrics, Yeungnam University College of Medicine, Daegu, Korea.
- KMID: 2157629
- DOI: http://doi.org/10.3346/jkms.2003.18.2.242
Abstract
- Autologous stem cell transplantation (ASCT) for the treatment of high-risk neuroblastoma (NBL) is an accepted method for restoring bone marrow depression after high dose chemotherapy. We retrospectively analyzed eighty eight cases of NBL that underwent ASCT following marrow ablative therapy at 12 transplant centers of the Korean Society of Pediatric Hematology-Oncology between January 1996 and September 2000. Seventy nine children were of stage IV NBL and 9 were of stage III with N-myc amplification. Various cytoreductive regimens were used. However, the main regimen was 'CEM' consisting of carboplatin, etoposide and melphalan, and this was used in 66 patients. Total body irradiation was also added in 36 patients for myeloablation. To reduce tumor cell contamination, stem cell infusions after CD34+ cell selection were performed in 16 patients. Post-transplantation therapies included the second transplantation in 18 patients, interleukin2 therapy in 45, 13-cis retinoic acid in 40, 131-meta-iodobenzylguanidine in 4, conventional chemotherapy in 11, and local radiotherapy in 8. Twenty two patients died, sixty six patients are surviving 1 to 46 months after ASCT (median followup duration, 14.5 months). Although the follow-up period was short and the number of patients small, we believe that ASCT might improve the survival rate in high-risk NBL.
Keyword
MeSH Terms
-
Adolescent
Child
Child, Preschool
Combined Modality Therapy
Female
Human
Korea
Male
Myeloablative Agonists/therapeutic use
Neuroblastoma/mortality
Neuroblastoma/pathology
Neuroblastoma/therapy*
Retrospective Studies
Stem Cell Transplantation*
Survival Rate
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Cited by 1 articles
-
Retrospective Analysis of Peripheral Blood Stem Cell Transplantation for the Treatment of High-Risk Neuroblastoma
Eun Kyung Kim, Hyoung Jin Kang, Jeong Ah Park, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn
J Korean Med Sci. 2007;22(Suppl):S66-S72. doi: 10.3346/jkms.2007.22.S.S66.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Palliative effect of (131)I-MIBG in relapsed neuroblastoma after autologous peripheral blood stem cell transplantation
- A Case of Autologous Cord Blood Stem Cell Transplantationin Stage IV Neuroblastoma
- Allogeneic stem cell transplantation for neuroblastoma
- A Case of Scleroderma following Autologous Peripheral Stem Cell Transplantation
- Early-onset Pericardial Effusion after Autologous Hematopoietic Stem Cell Transplantation in a Child with Neuroblastoma
